Combination with other antiretroviral agents. Medical search. Frequent questions

Home page Questions and answers Statistics Donations Contact

Anatomy3

CD4-Positive T-Lymphocytes Plasma CD8-Positive T-Lymphocytes

Organisms2

Diseases21

HIV Infections Acquired Immunodeficiency Syndrome AIDS-Related Opportunistic Infections HIV-Associated Lipodystrophy Syndrome HIV Seropositivity Pregnancy Complications, Infectious Viremia Immune Reconstitution Inflammatory Syndrome AIDS Dementia Complex Coinfection Lymphoma, AIDS-Related Lipodystrophy HIV Wasting Syndrome Cytomegalovirus Retinitis Tuberculosis Disease Progression AIDS-Associated Nephropathy Acidosis, Lactic Substance Abuse, Intravenous Sarcoma, Kaposi Hepatitis C

Chemicals and Drugs36

Anti-HIV Agents Indinavir Anti-Retroviral Agents Reverse Transcriptase Inhibitors HIV Protease Inhibitors Zidovudine Nelfinavir Organophosphonates Adenine Didanosine Ritonavir Nevirapine Benzoxazines Lopinavir HIV Integrase Inhibitors Dideoxyadenosine Dideoxynucleosides Lamivudine HIV Reverse Transcriptase Antiviral Agents RNA, Viral Protease Inhibitors Stavudine Pyridines Pyrimidinones HIV Protease Oxazines Saquinavir Antitubercular Agents pol Gene Products, Human Immunodeficiency Virus Pyrrolidinones HIV Fusion Inhibitors Cyclohexanes DNA, Viral Integrase Inhibitors Drugs, Generic

Analytical, Diagnostic and Therapeutic Techniques and Equipment26

Antiretroviral Therapy, Highly Active CD4 Lymphocyte Count Viral Load Drug Therapy, Combination Treatment Outcome Cohort Studies Treatment Failure Lost to Follow-Up Drug Monitoring Drug Administration Schedule Directly Observed Therapy Prospective Studies Retrospective Studies Risk Factors Cross-Sectional Studies Follow-Up Studies Prevalence Longitudinal Studies Withholding Treatment CD4-CD8 Ratio Incidence Chemoprevention Multivariate Analysis Lymphocyte Count Proportional Hazards Models Logistic Models

Psychiatry and Psychology5

Medication Adherence Patient Compliance AIDS Dementia Complex Treatment Refusal Substance Abuse, Intravenous

Phenomena and Processes16

Drug Resistance, Viral CD4 Lymphocyte Count Viral Load Drug Interactions Virus Replication Drug Resistance, Multiple, Viral Time Factors Pregnancy Genotype CD4-CD8 Ratio Mutation HIV Seronegativity Lymphocyte Count Genes, pol Viral Tropism Virus Latency

Anthropology, Education, Sociology and Social Phenomena2

Developing Countries Treatment Refusal

Information Science2

Prevalence Incidence

Named Groups2

HIV Long-Term Survivors Infant, Newborn

Health Care22

Infectious Disease Transmission, Vertical Treatment Outcome Medication Adherence Patient Compliance Cohort Studies Treatment Failure Prospective Studies Retrospective Studies Risk Factors Cross-Sectional Studies Follow-Up Studies Prevalence Longitudinal Studies Withholding Treatment Treatment Refusal Incidence Health Services Accessibility Multivariate Analysis Proportional Hazards Models Logistic Models Health Resources Rural Population

Geographicals22

South Africa Uganda Botswana Malawi Cote d'Ivoire Africa South of the Sahara Zambia Africa, Southern Zimbabwe Lesotho Thailand Cameroon Kenya Rwanda Haiti British Columbia Tanzania Cambodia Brazil Africa United States India

Anatomy Organisms Diseases Chemicals and Drugs Analytical, Diagnostic and Therapeutic Techniques and Equipment Psychiatry and Psychology Phenomena and Processes Anthropology, Education, Sociology and Social Phenomena Information Science Named Groups Health Care Geographicals

Anti-HIV Agents HIV Infections Indinavir HIV-1 Antiretroviral Therapy, Highly Active Anti-Retroviral Agents Reverse Transcriptase Inhibitors HIV Protease Inhibitors Zidovudine Drug Resistance, Viral CD4 Lymphocyte Count Viral Load Nelfinavir Organophosphonates HIV Adenine Didanosine Acquired Immunodeficiency Syndrome Ritonavir Nevirapine Benzoxazines Infectious Disease Transmission, Vertical Drug Therapy, Combination Drug Interactions Lopinavir HIV Integrase Inhibitors Dideoxyadenosine Dideoxynucleosides Lamivudine HIV Reverse Transcriptase Antiviral Agents RNA, Viral Protease Inhibitors Treatment Outcome Virus Replication Medication Adherence South Africa AIDS-Related Opportunistic Infections Stavudine Pyridines Patient Compliance HIV-Associated Lipodystrophy Syndrome Cohort Studies HIV Seropositivity Pregnancy Complications, Infectious Drug Resistance, Multiple, Viral Uganda Treatment Failure Viremia Immune Reconstitution Inflammatory Syndrome CD4-Positive T-Lymphocytes Botswana Lost to Follow-Up Pyrimidinones AIDS Dementia Complex Malawi Drug Monitoring Coinfection Drug Administration Schedule Cote d'Ivoire Africa South of the Sahara Directly Observed Therapy HIV Protease Prospective Studies Zambia Lymphoma, AIDS-Related Lipodystrophy Oxazines Retrospective Studies Time Factors Risk Factors Saquinavir Africa, Southern Cross-Sectional Studies Developing Countries Zimbabwe HIV Wasting Syndrome Cytomegalovirus Retinitis Pregnancy Tuberculosis Follow-Up Studies Prevalence Antitubercular Agents Plasma Disease Progression Lesotho pol Gene Products, Human Immunodeficiency Virus Genotype Longitudinal Studies Withholding Treatment Pyrrolidinones HIV Fusion Inhibitors Treatment Refusal CD4-CD8 Ratio Incidence Thailand HIV Long-Term Survivors Cameroon Kenya AIDS-Associated Nephropathy

No FAQ available that match "combination with other antiretroviral agents"